Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 2/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL920722 | 0.84 | MAPK14 (0.61) | HDAC6HPGDMAPK8LMNASMN1; SMN2 | |
| SCHEMBL3586286 | 0.83 | HDAC6 (0.53) | HDAC6KMT2AHPGDNSD2LMNA | |
| SCHEMBL923044 | 0.83 | KMT2A (0.70) | HDAC6KMT2AHPGDNSD2LMNA | |
| SCHEMBL3571438 | 0.82 | HPGD (0.64) | HDAC6KMT2AHPGDNSD2LMNA | |
| SCHEMBL921272 | 0.82 | MT-CO2 (0.54) | HDAC6KMT2AHPGDNSD2PRKCI | |
| SCHEMBL27824616 | 0.82 | NSD2 (0.56) | HDAC6KMT2AHPGDNSD2PRKCI | |
| SCHEMBL922492 | 0.82 | NSD2 (0.66) | KMT2AHPGDNSD2PRKCIMAPK8 | |
| SCHEMBL921161 | 0.81 | HPGD (0.56) | HDAC6KMT2AHPGDNSD2PRKCI | |
| SCHEMBL920122 | 0.81 | HPGD (0.68) | KMT2AHPGDNSD2PRKCILMNA | |
| SCHEMBL921118 | 0.80 | PRKCI (0.51) | HDAC6KMT2AHPGDNSD2PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | AADAT, AAAS, AADAC | HDAC6 1130/4885KMT2A 341/4885HPGD 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.